NG13-2 Clinical Study: MHRA Scientific Advisory Meeting on Clinical Study Design and Approval Path
18th -September- 2025
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly cost-effective therapies for the prevention/reduction of debilitating side-effects induced by anti-cancer treatments, is pleased to have completed a successful Scientific Advisory meeting with UK Medicines and Healthcare products Regulatory Agency (MHRA) on 18th September. on the planned Phase 2/3 clinical development and market approval path of the innovative NG13-2 scalp-topical medicine for the prevention of chemotherapy-induced alopecia (hair-loss), with positive feedback on the trial design and market approval path, the written response is expected in late October 2025.
Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:
"We are pleased to have received the positive feedback along with detailed supportive advice during a fruitful Scientific Advisory meeting. We appreciate the MHRA granted us this opportunity to discuss the NG13-2 Phase2/3 trial design and further development in detail, providing a roadmap for bringing our NG13-2 product to the market in the near future!"
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company's proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.